Two Oral Cancer Drugs Effective in 'Steve Jobs' Disease, University of Texas MD Anderson Cancer Center Study

Most Popular posts from other blogs...

Free Newsletters
Archive
My eNewsletters

News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Login
Become a Member
Discussion Forums
FAQ

Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia

Career Definitions
Labor Market Reports
Education & Training
Regions


Market Summary
News
IPOs

Company Profiles

Companies
Events

Research Store

Biotech Events
Post an Event
Real Estate
Business Opportunities

Two Oral Cancer Drugs Effective in 'Steve Jobs' Disease, University of Texas MD Anderson Cancer Center Study
2/10/2011

MedPageToday -- Two small-molecule kinase inhibitors appear to be effective at extending progression-free survival in pancreatic neuroendocrine tumors, researchers say. In patients with advanced disease enrolled in phase III trials, both everolimus, an mTOR inhibitor, and sunitinib, a tyrosine kinase inhibitor, each halted disease progression significantly longer than placebo, according to two studies in the Feb. 10 issue of the New England Journal of Medicine.